Hospitalization for patients in the United States (US) and European Union (EU) treated with inotuzumab ozogamicin (InO) vs standard of care (SOC) for relapsed/refractory acute lymphoblastic leukemia (R/R ALL) in a global phase 3 trial.

Yun Su,Ilse van Oostrum,Erik Vandendries,Verna Welch,Fausto R. Loberiza

Hospitalization for patients in the United States (US) and European Union (EU) treated with inotuzumab ozogamicin (InO) vs standard of care (SOC) for relapsed/refractory acute lymphoblastic leukemia (R/R ALL) in a global phase 3 trial.

2017

Yun Su
Ilse van Oostrum
Erik Vandendries
Verna Welch
Fausto R. Loberiza

e18500Background: InO, an anti-CD22 antibody-calicheamicin conjugate, with its once a week, 1-hour infusion schedule, has demonstrated lower hospital utilization in association with superior clinic...

Keywords:

Refractory
Inotuzumab ozogamicin
European union
Pediatrics
Physical therapy
Lymphoblastic Leukemia
Medicine
hospital utilization
standard of care
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations